FDX1 and liver cancer: Wang and colleagues recently observed that ferroptosis inducers, sorafenib and erastin, can enhance cuproptosis in primary liver cancer cells, mainly through upregulating FDX1 protein levels and promoting the aggregation of lipoylated proteins [73].